Isodiol International Inc. Reports Q1 Unaudited Financial Statements
August 29th, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products reports Q1 revenue for the period ended June 30, 2017 of $2,740,542 compared to Q1 revenue in 2016 of $47,185. The substantial increase in revenue is attributed to the acquisition of its wholly owned US subsidiary, Iso International LLC on May 15, 2017, which is also the consolidation date for this reporting period.
The Company experienced a Net Income Loss from operations of $8,478 after adding back non-cash items such as Stock Based Payments compared to Q1 2016 Net Income Loss from operations of $291,891. This significant decrease in operational loss can be attributed to the Company developing and marketing an improved product portfolio and successful implementing its global expansion into the US and Latin America.
Since the beginning of Q2 which commenced July 1, the Company has successfully gained further traction in Latin America through its launch of Isoderm and will continue to expand in this region with the introduction of additional products. The Company is also excited to further roll-out and execute its expansion plans in Q2 for penetration into Europe, Asia and the Australian markets.
Marcos Agramont, CEO of Isodiol International Inc. stated, “The company is nearing the completion of significant milestones through the collaboration with its partners in Latin America. We have been fortunate to have partnered with a group who is very influential with the regulators and health professionals in that region. Our Q1 financials show a significant improvement from prior year and we anticipate further month over month growth heading into the fall.”
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA:
Isodiol.com
CBDnaturals.com
Iso-sport
CBDskincream.com
Potocoffee
[email protected]
Join Us On Face Book: https://www.facebook.com/Isodiol/
Twitter: @isodiol
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.